Trial · NCT02029378
Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
NCT02029378, Phase 2, Unknown, NHS Greater Glasgow and Clyde
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study. Trials, record NCT02029378. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02029378
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
- NCT number
- NCT02029378
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Conditions
- Gullian Barre Syndrome
- Interventions
- Eculizumab
- First posted
- 2014-01-07
- Last updated
- 2014-09-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine the incidence of AE/SAEs after treatment with eculizumab and IVIg compared to placebo controls | 6 months | Primary safety endpoint |
| Primary | Improvement of one or more grade in functional outcome (on the 6 point GBS disability scale) at 4 weeks | 4 weeks | Primary efficacy endpoint |
| Secondary | Ability to walk unaided (GBS disability score 2) at 8 weeks | 8 weeks | |
| Secondary | Time taken to improve by at least one grade (on the GBS disability scale) | 8 weeks | |
| Secondary | Time taken to walk independently | 1 year | |
| Secondary | Difference in GBS disability score at maximum disability completed with 6 months | 6 months | |
| Secondary | Percentage of patients with a clinically relevant improvement in R-ODS score | 6 months | An increase from Baseline in R-ODS score by at least 6 points on the centile metric score at 4 weeks and 6 months |
| Secondary | Percentage of patients with a clinically relevant improvement in ONLS | 6 months | Defined as an increase from baseline in ONLS score by at least 1 point at 4 weeks and 6 months |
| Secondary | Requirement for ventilatory support (GBS disability score 5) | 4 weeks | |
| Secondary | Duration of ventilatory support | 8 weeks |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27801990 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02029378
GET https://conductscience.org/api/trials/v1/NCT02029378/registered